Stocktoria
BRISTOL MYERS SQUIBB CO BMY
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 1980-03-17
BRISTOL MYERS SQUIBB CO financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $48.2B | $48.3B | $45.0B | $46.2B | $46.4B |
| R&D expense | $10.0B | $11.2B | $9.3B | $9.5B | $10.2B |
| SG&A expense | $7.3B | $8.4B | $7.8B | $7.8B | $7.7B |
| Interest expense | — | — | $1.2B | $1.2B | $1.3B |
| Income tax | $2.3B | $554.0M | $400.0M | $1.4B | $1.1B |
| Net income | $7.1B | -$8.9B | $8.0B | $6.3B | $7.0B |
| EPS (diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
| Operating cash flow | $14.2B | $15.2B | $13.9B | $13.1B | $16.2B |
| Free cash flow | $12.8B | $13.9B | $12.7B | $11.9B | $15.2B |
| Cash & equivalents | $10.2B | $10.3B | $11.5B | $9.1B | $14.0B |
| Inventory | $2.7B | $2.6B | $2.7B | $2.3B | $2.1B |
| Total assets | $90.0B | $92.6B | $95.2B | $96.8B | $109.3B |
| Total liabilities | $71.5B | $76.2B | $65.7B | $65.7B | $73.3B |
| Shareholders' equity | $18.5B | $16.4B | $29.5B | $31.1B | $36.0B |
Source: SEC EDGAR filings · CIK 0000014272 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.